Exbivirumab is a human monoclonal antibody[1] developed for the treatment of hepatitis B infections.[2]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | hepatitis B surface antigen |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6416H9924N1732O1982S44 |
| Molar mass | 144446.75 g·mol−1 |
  (what is this?) (verify) | |
References
edit- ^ "WHO Drug Information" (PDF). Archived from the original (PDF) on 2011-05-11. Retrieved 2009-09-24.
- ^ Shouval D, Terrault N, Galun E, Samuel D, Gane E, Pruett T, et al. (2006). "Anti-Viral Effects, Pharmacokinetics and Safety of Two Human Monoclonal Anti-Hbs (Libivirumab/Exbivirumab) Versus Hepatitis B Immune Globulin (Hbig) in Hepatitis B Virus (Hbv) in Liver Transplant (Lt) Recipients". Hepatology. 44 (4): 188A–700A [196A]. doi:10.1002/hep.21395.
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |